Our study discovered a relatively higher anti‐AR positivity ratio in Xp11.2 tRCC than in ccRCC (56.5% vs. 30.8%), although the difference was not statistically significant. Here, AR is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.